https://www.clinicaltrialsarena.com/news/bellerophon-therapeutics-fild-trial/ Another company fails to make a difference to Pulmonay Fibrosis management. Using ambulatory inhaled Nirtic Oxide (currently NOxide used successfully in ICU for temporary severe Pulmonary Hypertension management). Logically this would only address symptoms and possibly slow secondary right heart failure rather than address the causative fibrosis. ATX has a massive potential here.
https://www.clinicaltrialsarena.com/news/bellerophon-therapeutics...
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.002(2.86%) |
Mkt cap ! $19.55M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.2¢ | 7.0¢ | $5.99K | 84.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 819 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 8120 | 1 |
View Market Depth
| Last trade - 15.43pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.002 ( 1.41 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.2¢ | 7.2¢ | 7895 | ||
| Last updated 13.20pm 06/06/2024 ? | |||||
| ATX (ASX) Chart |